Isarna Therapeutics isarna-therapeutics.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Isarna Therapeutics has a commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. The company is advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Isarna Therapeutics has a commitment to developing TGF-β inhibitors that stimulate the human immune system to effectively fight cancer. The company is advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clin...Show all

Company (Alive / Active)

Phone: +49-89-890831-0

Fax:

Leopoldstrasse 254-256

Munich, D-80807
Germany

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Isarna Therapeutics $112.6M Apr 24, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Isarna Therapeutics Jobs

jobs by Indeed job
						search
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Modified tgf-beta oligonucleotides Jan 29, 2018 Jan 21, 2020 Patent
Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease May 12, 2017 Nov 13, 2018 Patent
Modified tgf-beta oligonucleotides Mar 27, 2014 Mar 27, 2018 Patent
Modified tgf-beta2 oligonucleotides Mar 27, 2014 Dec 12, 2017 Patent
Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease Mar 27, 2014 Jun 27, 2017 Patent
See all 8 patents